Browsing Tag
CERo Therapeutics
1 post
CERo Therapeutics moves forward in Phase 1 AML study as CER-1236 passes first-dose safety review
CERo Therapeutics completes first cohort of its Phase 1 AML trial with no dose-limiting toxicities—discover how CER-1236 could reshape immunotherapy.